A growing number of studies have demonstrated that the expression of programmed cell death receptor 1 (PD-1) and its ligand (PD-L1), a new target for tumor immunotherapy, can reflect the objective response rate (ORR) and overall survival (OS) of some cancer patients. The gene discussed is CD274; the disease is cancer.